Fast Delivery Sofosbuvir CAS No. 1190307-88-0

• CAS No.: 1190307-88-0
• Formula: C22h29fn3o9p
• EINECS: 695-717-4
• Type: Synthesis Material Intermediates
• Appearance: Powder
• Quality: Refined
• Model NO.: 1190307-88-0
• Colour: White
• Transport Package: Customers′ Requirement
• Origin: China
• Production Capacity: 30000

Product Description

  

 

Product Description

Product Name: Sofosbuvir

CAS: 1190307-88-0

Product Name	Sofosbuvir
CAS	1190307-88-0
MF	C22H29FN3O9P
MW	529.45
Density	1.41
pka	9.39±0.10
Shelf life	2 Years
Molecular formula

Sofebuvir, also known as Sofibuvesoflubuvir, is the world's first oral treatment for hepatitis C. It is one of the most important new drugs approved in the United States in 2013. When used for the treatment of specific genotypes of chronic hepatitis C, it eliminates the need for traditional injectable interferon (IFN), made by the world's largest manufacturer of anti-HIV drugs The success of gilead Sciences, known in English as Sofosbuvir Sovaldi, could peak global sales at more than $10 billion On December 6, 2013, the US Food and Drug Administration (FDA) approved Sovaldi for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi is the first safe and effective treatment for certain types of HCV infection without the need for interferon concomitant therapy

 

Detailed Photos

 

Company Profile

 

Packaging & Shipping

FAQ

Q1: Can I get a sample?
A: We can provide our clients small sample (Sample size form 1-50 grams). Free samples can be provided for some products due to the material cost.

Q2:How to start orders or make payments?
A: You can send us your Purchase Order (PO), or just send a simple confirmation by email or by Trade Manager.

Q3: What's your Minimum Ordering Quantity (MOQ)?
A: Products' MOQ depend on their value, please kindly confirm specific items with our online sales.

Q4: Is there a discount?
A: Yes, we offer low prices for larger quantities. There will be different price range on our quotation list so please inform us with quantity you will be after.